Social media

Early phase neurodegenerative trials require careful planning, a patient-first approach, and biomarker strategies that drive progress. Tune in to our recent ASCPT-hosted webinar, where we explored: - How to define target...

Innovation is accelerating progress in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions bring together advanced formulation design, real-time dose flexibility, and world-class CMC expertise to si...

Innovation is accelerating progress in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions bring together advanced formulation design, real-time dose flexibility, and world-class CMC expertise to si...

ICON is proud to be recognised among the top global companies in the world for female employees. As of 31 December 2024, women make up 70% of our workforce and hold 60% of director-level and above roles—a powerful refle...

ICON is proud to be recognised among the top global companies in the world for female employees. This recognition is based on a comprehensive survey of approximately 120,000 women across more than 36 countries, highlight...

With PubsHub Journals & Congresses, you’ll receive real-time alerts for updates, extensions, and changes to deadlines on your personalized watch list. That means fewer surprises - and better decisions. See how easy it is...

With PubsHub Journals & Congresses, you’ll receive real-time alerts for updates, extensions, and changes to deadlines on your personalized watch list. That means fewer surprises - and better decisions. See how easy it is...

Data is the foundation of every decision in clinical development, yet the journey from first patient interaction to final submission is rarely seen in full. Our latest blog takes you behind the scenes to explore how inf...

Data is the foundation of every decision in clinical development, yet the journey from first patient interaction to final submission is rarely seen in full. Our latest blog takes you behind the scenes to explore how inf...

Central laboratories are under more pressure than ever. Increasingly complex protocols, frequent amendments, and growing data demands require speed, agility, and uncompromising scientific integrity. At ICON Laboratories,...

Traditional trial settings often fail to reveal the added value of emerging HIV therapies. Explore how developers can plan trials that demonstrate the true advantages and utility of an HIV intervention in the article fro...

While multi-pronged global health efforts are essential to combatting HIV, systemic impediments persist. In ICON’s article, learn how drug developers can play a role in reshaping the future of HIV control, and what they ...